Health Care & Life Sciences » Biotechnology | Kura Oncology Inc.

Kura Oncology Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2014
2015
2016
2017
2018
Cash & Short Term Investments
1,123.90
85,746.00
67,790.00
93,145.00
178,985
Total Accounts Receivable
30.10
430.00
295.00
216.00
224
Other Current Assets
42.60
693.00
725.00
1,280.00
1,988
Total Current Assets
1,196.60
86,869.00
68,810.00
94,641.00
181,197
Net Property, Plant & Equipment
26.60
71.00
40.00
10.00
-
Other Assets
154.60
319.00
971.00
1,200.00
1,182
Total Assets
1,377.80
87,259.00
69,821.00
95,851.00
182,379
ST Debt & Current Portion LT Debt
2,035.60
-
-
1,531.00
Accounts Payable
360.20
-
770.00
1,464.00
Other Current Liabilities
620.10
5,055.00
4,681.00
7,036.00
Total Current Liabilities
3,015.80
5,055.00
5,451.00
10,031.00
Long-Term Debt
493.40
-
7,324.00
5,567.00
Other Liabilities
1,302.10
101.00
170.00
388.00
Total Liabilities
4,811.30
5,156.00
12,945.00
15,986.00
Common Equity (Total)
3,433.50
82,103.00
56,876.00
79,865.00
Total Shareholders' Equity
3,433.50
82,103.00
56,876.00
79,865.00
Total Equity
3,433.50
82,103.00
56,876.00
79,865.00
Liabilities & Shareholders' Equity
1,377.80
87,259.00
69,821.00
95,851.00

About Kura Oncology

View Profile
Address
3033 Science Park Road
San Diego California 92121
United States
Employees -
Website http://www.kuraoncology.com
Updated 07/08/2019
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E.